Showing results (91-100 of 122) with videos related to
Sort By:
Pageof 13
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 18, 2013
Gender affects acute organ toxicity during radiochemotherapy for rectal cancer: long-term results of the German CAO/ARO/AIO-94 phase III trialHendrik Andreas Wolff, Lena-Christin Conradi, Tim Beissbarth, et al.International Journal of Molecular Sciences|February 26, 2025
Exosomal CD40, CD25, and Serum CA19-9 as Combinatory Novel Liquid Biopsy Biomarker for the Diagnosis and Prognosis of Patients with Pancreatic Ductal AdenocarcinomaPaul David, Dina Kouhestani, Frederik J Hansen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2023
Risk-Adapted Neoadjuvant Chemoradiotherapy in Rectal Cancer: Final Report of the OCUM StudyReinhard Ruppert, Theodor Junginger, Rainer Kube, et al.European Journal of Radiology|January 13, 2022
Selection of patients with rectal cancer for neoadjuvant therapy using pre-therapeutic MRI - Results from OCUM trialSigmar Stelzner, Reinhard Ruppert, Rainer Kube, et al.Annals of Surgical Oncology|August 16, 2019
MRI-Based Use of Neoadjuvant Chemoradiotherapy in Rectal Carcinoma: Surgical Quality and Histopathological Outcome of the OCUM TrialMartin E Kreis, Reinhard Ruppert, Rainer Kube, et al.Cancers|June 22, 2023
Tumor-Stroma Ratio in Colorectal Cancer-Comparison between Human Estimation and Automated AssessmentDaniel Firmbach, Michaela Benz, Petr Kuritcyn, et al.International Journal of Cancer|June 9, 2025
Integrin β6 expression in colorectal cancer cells promotes liver metastasis through enhanced adhesion to endothelial fibronectinChiara Van Passen, Julia Krug, Luisa Weiß, et al.Cancers|January 21, 2023
Circulating Monocytes Serve as Novel Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma PatientsFrederik J Hansen, Paul David, Marina Akram, et al.Oncology|October 20, 2021
A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic Colorectal Cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI - Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPAK II Trial with Early ResultsAxel Wein, Robert Stoehr, Stephan Kersting, et al.Gastroenterology|September 21, 2023
p21 Prevents the Exhaustion of CD4+ T Cells Within the Antitumor Immune Response Against Colorectal CancerOana-Maria Thoma, Elisabeth Naschberger, Markéta Kubánková, et al.Pageof 13